Image generated by CariGold
Regencell Bioscience Stock Skyrockets as 38-to-1 Split Takes Effect
Key Takeaways
It's been quite a good month for investors in Regencell Bioscience Holdings (RGC).
Shares of the Hong Kong firm that focuses on the use of traditional Chinese medicine to treat Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD) in children more than quadrupled on the first day a huge 38-to-1 stock split took effect.
The company announced the split on June 2, and that the stock would be distributed on June 13.
Regencell said the move was intended to "enhance liquidity in the market for the Company's ordinary shares and make the shares more accessible to investors."
This article has been published in Investopedia via Yahoo News.
